US panel to review Ovation's Sabril for epilepsy
This article was originally published in Scrip
Executive Summary
The US FDA's peripheral and central nervous system drugs advisory panel will meet for two days next month to evaluate Ovation's epilepsy drug Sabril (vigabatrin). On August 6th the committee will discuss the NDA for adjunctive therapy in treating refractory partial seizures in adults. Vigabatrin's use for infantile spasms will be considered on August 7th. Both indications are undergoing a priority review; the user fee deadline was June 30th, but the FDA has informed the company that it expects to take an additional two months. Ovation said it anticipates receiving an action letter by the end of August and a final decision in the fourth quarter. The company acquired North American rights for Sabril, an irreversible GABA-transaminase inhibitor, from Aventis (nowSanofi-Aventis) in 2004. Vigabatrin is marketed for epilepsy in more than 50 countries but has been associated with visual field defects. The drug is also being tested in the US as a treatment for methamphetamine and cocaine dependence.
You may also be interested in...
Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing
Commissioner Robert Califf discussed the agency’s request for $12.3m to address shortages and legislation to require that manufacturers provide more detailed information about increased demand and supply chain vulnerabilities.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
US FDA Drugs Center Launches Clinical Trial Innovation Hub With Demonstration Projects
CDER’s Center for Clinical Trial Innovation (C3TI) will support innovative clinical trial approaches designed to improve the quality and efficiency of drug development and regulatory decision-making. The initiative includes demonstration projects on Bayesian analyses, selective safety data collection and point-of-care trials.